“Dominolike” Barriers Elimination with an Intratumoral Adenosine-Triphosphate-Supersensitive Nanogel to Enhance Cancer Chemoimmunotherapy
Source abstract
Abstract
Pathophysiological barriers in “cold” tumors seriously limit the clinical outcomes of chemoimmunotherapy. These barriers distribute in a spatial order in tumors, including immunosuppressive microenvironment, overexpressed chemokine receptors, and dense tumor mesenchyme, which require a sequential elimination in therapeutics. Herein, we reported a “dominolike” barriers elimination strategy by an intratumoral ATP supersensitive nanogel (denoted as B BLZ-945 @PAC–PTX) for enhanced chemoimmunotherapy. Once it has reached the tumor site, B BLZ-945 @PAC–PTX nanogel undergoes supersensitive collapse triggered by adenosine triphosphate (ATP) in perivascular regions and releases BLZ-945 conjugated albumin (B BLZ-945 ) to deplete tumor-associated macrophages (TAMs). Deeper spatial penetration of shrunk nanogel (PAC–PTX) could not only block CXCR4 on the cell membrane to decrease immunosuppressive cell recruitment but also internalize into tumor cells for tumor-killing and T cell priming. The strategy of “dominolike” barriers elimination in tumors enables immune cell infiltration for a potentiated immune response and offers a high-responsive treatment opinion for chemoimmunotherapy.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Nanoparticle-Based Drug Delivery · Immune cells in cancer
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
State Key Laboratory of Natural Medicines and Department of Pharmaceutics, China Pharmaceutical University, Nanjing, Jiangsu 210009, China
Nanjing Branch, Jiangsu Yuanchuang Pharmaceutical Research and Development Co., Ltd., Nanjing, Jiangsu 210000, China
Department of Neurosurgery, The First People’s Hospital of Changzhou, Changzhou, Jiangsu 213000, China
Funding
Natural Science Foundation of Jiangsu Province · National Natural Science Foundation of China
References (30)
Show source-provided references
1. 10.1038/nrc323910.1038/nrc3239 ↗
2. 10.1002/adma.20180332210.1002/adma.201803322 ↗
3. 10.1038/nature1395410.1038/nature13954 ↗
4. 10.1038/s41591-018-0014-x10.1038/s41591-018-0014-x ↗
5. 10.1007/s00262-013-1434-610.1007/s00262-013-1434-6 ↗
6. 10.1038/s41568-019-0125-910.1038/s41568-019-0125-9 ↗
7. 10.1016/j.immuni.2014.06.01010.1016/j.immuni.2014.06.010 ↗
8. 10.1038/nrclinonc.2015.20910.1038/nrclinonc.2015.209 ↗
9. 10.1126/science.125251010.1126/science.1252510 ↗
10. 10.1007/s13277-015-3189-510.1007/s13277-015-3189-5 ↗
11. 10.1111/cas.1216710.1111/cas.12167 ↗
12. 10.1182/blood-2011-09-37921410.1182/blood-2011-09-379214 ↗
13. 10.1016/j.ccr.2014.05.01610.1016/j.ccr.2014.05.016 ↗
14. 10.1038/nm.339410.1038/nm.3394 ↗
15. 10.1039/C6CS00458J10.1039/C6CS00458J ↗
16. 10.1158/2159-8290.CD-15-152310.1158/2159-8290.CD-15-1523 ↗
17. 10.1016/j.it.2016.04.01010.1016/j.it.2016.04.010 ↗
18. 10.1016/j.lungcan.2011.11.02210.1016/j.lungcan.2011.11.022 ↗
19. 10.1186/s12894-019-0507-z10.1186/s12894-019-0507-z ↗
20. 10.1038/s41551-018-0254-610.1038/s41551-018-0254-6 ↗
21. 10.1021/acsami.8b1330010.1021/acsami.8b13300 ↗
22. 10.1038/ncomms436410.1038/ncomms4364 ↗
23. 10.7150/thno.2834410.7150/thno.28344 ↗
24. 10.1021/acs.nanolett.7b0119310.1021/acs.nanolett.7b01193 ↗
25. 10.1016/j.coi.2015.06.00710.1016/j.coi.2015.06.007 ↗
26. 10.1016/j.ccell.2015.10.01210.1016/j.ccell.2015.10.012 ↗
27. 10.1016/j.nano.2013.07.00710.1016/j.nano.2013.07.007 ↗
28. 10.1002/jlb.41.1.8310.1002/jlb.41.1.83 ↗
29. 10.1016/j.ijpharm.2016.07.02010.1016/j.ijpharm.2016.07.020 ↗
30. 10.1021/acsnano.6b0232610.1021/acsnano.6b02326 ↗